In addition, inhibitors of a defective TCA cycle enzyme, the isocitrate dehydrogenase (AG120/ivosidenib, and AG221/enasidenib), have been FDA-approved for treating IDH-mutated relapsed/refractory AML [7,8,16]. The gene discussed is IDH2; the disease is acute myeloid leukemia.